MDT

96.16

-0.35%↓

137.54

-0.56%↓

VEEV

224.48

-0.38%↓

HQY

92.86

+0.09%↑

PHR.US

16.92

-0.12%↓

MDT

96.16

-0.35%↓

137.54

-0.56%↓

VEEV

224.48

-0.38%↓

HQY

92.86

+0.09%↑

PHR.US

16.92

-0.12%↓

MDT

96.16

-0.35%↓

137.54

-0.56%↓

VEEV

224.48

-0.38%↓

HQY

92.86

+0.09%↑

PHR.US

16.92

-0.12%↓

MDT

96.16

-0.35%↓

137.54

-0.56%↓

VEEV

224.48

-0.38%↓

HQY

92.86

+0.09%↑

PHR.US

16.92

-0.12%↓

MDT

96.16

-0.35%↓

137.54

-0.56%↓

VEEV

224.48

-0.38%↓

HQY

92.86

+0.09%↑

PHR.US

16.92

-0.12%↓

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Open

SectorGezondheidszorg

13.87 -3.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.87

Max

14.35

Belangrijke statistieken
By Trading Economics
Inkomsten	-217K -19M
Verkoop	86K 86K
EPS	-0.29
Winstmarge	-22,540.698
Werknemers	75
EBITDA	-228K -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+52.78% upside

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-179M 958M
Vorige openingsprijs	17.01
Vorige sluitingsprijs	13.87

Nieuwssentiment

By Acuity

29%

71%

68 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 dec 2025, 22:03 UTC

Belangrijke Marktbewegers

Mining Stocks Slip Near the End of Stellar Year

29 dec 2025, 15:57 UTC

Belangrijke Marktbewegers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Operate From Singapore

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec 2025, 23:37 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Integrate Manus Service Into Products

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec 2025, 23:35 UTC

Acquisities, Fusies, Overnames

Manus to Join Meta Platforms

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Raise Values Kraken at US$8.65 Billion

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin's Kraken Stake to Remain at 22.7%

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin: Additional Interest Offsets Dilution From Raise

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec 2025, 20:22 UTC

Marktinformatie

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec 2025, 20:02 UTC

Acquisities, Fusies, Overnames

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec 2025, 17:36 UTC

Marktinformatie

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

52.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD 52.78%

Hoogste 22 USD

Laagste 22 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

68 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.